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Tumour cytokinetics estimated in vivo as potential doubling times (Tpot values) have been found to range in a variety of human cancers
from 2 days to several weeks and are often related to clinical outcome. We have previously developed a method to estimate culture
cycle times of short-term cultures of surgical material for several tumour types and found, surprisingly, that their range was similar to
that reported for Tpot values. As Tpot is recognised as important prognostic variable in cancer, we wished to determine whether
culture cycle times had clinical significance. Brain tumour material obtained at surgery from 70 patients with glioblastoma,
medulloblastoma, astrocytoma, oligodendroglioma and metastatic melanoma was cultured for 7 days on 96-well plates, coated with
agarose to prevent proliferation of fibroblasts. Culture cycle times were estimated from relative
3H-thymidine incorporation in the
presence and absence of cell division. Patients were divided into two groups on the basis of culture cycle times of p10 days and
410 days and patient survival was compared. For patients with brain cancers of all types, median survival for the p10-day and 410-
day groups were 5.1 and 12.5 months, respectively (P¼0.0009). For 42 patients with glioblastoma, the corresponding values were
6.5 and 9.0 months, respectively (P¼0.03). Lower grade gliomas had longer median culture cycle times (16 days) than those of
medulloblastomas (9.9 days), glioblastomas (9.8 days) or melanomas (6.7 days). We conclude that culture cycle times determined
using short-term cultures of surgical material from brain tumours correlate with patient survival. Tumour cells thus appear to preserve
important cytokinetic characteristics when transferred to culture.
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In vivo tumour proliferation rates, initially estimated from the
percentages of either mitotic cells or S-phase cells, have long been
known to be related at least for some tumour types to clinical
outcome (Tannock, 1978). Other estimates of proliferative activity,
including staining with antibodies to antigens such as Ki-67 and
PCNA, and more recently, gene expression profiles (Nutt et al,
2003), have also been associated with clinical outcome in some
studies. Potential tumour doubling times (Tpot values) rely on
simultaneous measurement of S-phase percentage and S-phase
duration and provide more quantitative estimates, which for many
tumour types cover a range from 2 days to several weeks (Wilson
et al, 1988; Rew and Wilson, 2000). However, although short
Tpot values are generally related to poor prognosis, the value of
Tpot as an independent prognostic indicator is controversial
(Haustermans and Fowler, 2001), and in the case of brain cancers,
Tpot values are not clearly related to survival (Danova et al, 1988;
Struikmans et al, 1998).
We have previously investigated the possibility that data from
short-term cultures of clinical tumour material might have
prognostic significance (Marshall et al, 1992, 2003; Baguley et al,
2002), and we were particularly interested in the possibility of
using tumour material to estimate culture cycle time. Direct
measurement in such cultures is impossible because of the
presence of host cells in the sample and the loss of tumour cells,
through apoptosis or other pathways, during primary culture.
However, we had previously found using a series of human tumour
cell lines that the degree of incorporation of
3H-thymidine into
DNA at different times after addition of paclitaxel, an inhibitor of
mitosis and cell division, was a function of the measured culture
doubling time (Baguley et al, 1995). We assumed that culture-
doubling time was similar to culture cycle time for cell lines (i.e.,
that cell loss was negligible) and developed an empirical formula
that related culture cycle time to the
3H-thymidine data.
We then considered whether the above formula, obtained using
cell lines, might be applied to short-term (7-day) cultures of
tumour samples obtained at surgery. The nature of the assay
(comparison of
3H-thymidine incorporation with and without
paclitaxel) minimised the consequences of tumour cell loss during
culture because any cell loss would affect cultures with and without
paclitaxel almost equally. Surprisingly, culture cycle times
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sestimated in this manner were found to vary among individual
samples from approximately 2 days to more than 40 days, a range
that was remarkably similar to that obtained in Tpot measurements
(Baguley and Marshall, 2004). Furthermore, in a small study of 16
patients with ovarian cancer, derived culture cycle times were
found to be related to patient survival (Baguley and Marshall,
2004). Here, we have addressed the question of whether the same
approach might be applied to patients with brain tumours. We
cultured samples from a range of brain tumours and have also
included melanomas metastatic to the brain, as they are also
tumours derived from the neural crest. We then determined
whether culture cycle times derived by this approach were related
to overall survival.
MATERIALS AND METHODS
Culture of tumour samples
Patients received surgery in the Department of Neurosurgery,
Auckland City Hospital. All studies were carried under guidelines
approved by the Northern X Regional Ethics Committee, and
informed consent was obtained from all patients. A portion of
tumour tissue taken from patients undergoing surgery for brain
malignancies was placed in a-MEM growth medium containing
insulin (10mg/ml), transferrin (10mg/ml), selenite (10ng/ml) and
5% fetal bovine serum and was used either immediately or after
overnight storage at 41C. Tumour material was disaggregated to
form small cellular clusters to preserve, as far as possible, cell–cell
and cell–matrix interactions (Baguley et al, 2002). Preparations
were monitored by phase contrast microscopy and by examination
of haematoxylin/eosin-stained cytospins. Cell suspensions,
containing both single cells and cell clusters, were transferred to
96-well tissue culture plates that had previously been coated with a
thin layer of agarose to prevent the growth of fibroblasts and were
grown at 371C under an atmosphere of 5% O2,5 %C O 2 and 90% N2
(Marshall et al, 1992).
Determination of culture cycle times
Plates were set up to contain between 940 and 7500 cells in
a volume of 150ml, to allow selection of a cell density where
3H-thymidine incorporation after 7 days was proportional to the
initial number of cells added. Cultures were grown either in the
absence of drug or in the presence of paclitaxel at five 3-fold
concentration steps up to a maximum of 2mM. S-phase cells
remaining at the end of the incubation were labelled by the
addition of
3H-thymidine over the last 24h (Baguley et al, 1995).
Cultures were harvested and duplicate samples were analysed for
each paclitaxel dose with multiple control samples.
3H-thymidine
incorporation data in the presence of paclitaxel were fitted by a
least-squares fit to an exponential of the form y¼Pþae
 bx, where
y is the radioactivity (corrected for background), x is the paclitaxel
concentration and a and b are variables, as shown in the two
examples in Figure 1. Values of P therefore reflected the
proportion of remaining S-phase cells at the end of the incubation
period, which in turn reflected the proportion of G1-phase cells
that were feeding into S-phase. The estimated culture cycle time in
days (T) was calculated using an equation T¼ 3.78/(log10 P),
which was derived from empirical data obtained with cell lines
(Baguley et al, 1995). When P was 40.81 (T440), culture cycle
time was not accurately provided by this formula and was
arbitrarily set at 40 days.
Statistics
Median culture cycle times were compared using the Kruskall–
Wallis test, and proportions using a w
2 test. Survival was compared
using Kaplan–Meier survival curves with log rank tests and Cox
regression. Analysis was carried out using Stata version 9.
RESULTS
Incorporation of
3H-thymidine by primary cultures in the presence
of paclitaxel were found to decrease with increasing drug
concentration to a ‘plateau’ value (Figure 1) from which the
culture cycle time was calculated. Culture cycle times estimated
using this method ranged from 2 to X40 days, with a median of 10
days (Table 1). Survival times for the patients from whom tumour
samples were taken, together with data for age, gender, tumour
grade and treatment, are also shown in Table 1.
Table 2 compares survival and culture cycle times for the
different age, gender, tumour type and treatment groups. Survival
varied by age (P¼0.002) and the estimated median survival times
in months were 9.5 for those aged under 30 years, 30.7 for those
aged 30–50 years, 9.1 for those aged 50–59 years, 7.3 for those
aged 60–69 years and 2.6 for those aged 70 years and above. There
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Figure 1 Examples of
3H-thymidine incorporation as a function of paclitaxel concentration. Profiles are shown for patients D4 (A), S4 (B) and B6 (C),
with designations in Table 1.
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sTable 1 Clinical and biological data
Patient Age (years) Gender Tumour type Plateau (%)
a Culture cycle time (days) Survival (days)
b Radiotherapy
A1 86 M Glioblastoma 38 9.0 105 Yes
A2 74 M Metastatic melanoma 75 30.3 559 Yes
B1 54 F Glioblastoma 41 9.8 271 No
B2 14 F Glioblastoma 19 5.2 282 Yes
B3 68 F Glioblastoma 39 9.2 222 Yes
B4 67 F Glioblastoma 42 10 267 No
B5 57 M Astrocytoma, anaplastic 28 6.8 101
B6 52 M Glioblastoma 89 40.0 489* Yes
C1 73 M Glioblastoma 78 35.0 399 Yes
D1 32 M Medulloblastoma 55 14.6 343* Yes
D2 54 M Glioblastoma 55 14.6 368 Yes
D3 7 F Astrocytoma, pilocytic 55 14.6 289 No
D4 69 M Glioblastoma 46 11.2 104 Yes
E1 36 M Astrocytoma, anaplastic 66 20.9 3168 Yes
E2 49 M Oligodendroglioma, anaplastic 76 31.7 868* Yes
F1 2 M Glioblastoma 37 8.8 78 No
F2 72 M Glioblastoma 26 6.5 197 Yes
F3 74 F Glioblastoma 38 9.0 491
F3 68 M Metastatic melanoma 79 36.9 378 No
G1 43 M Astrocytoma, anaplastic 64 19.5 316* Yes
G2 13 M Glioblastoma 59 16.5 476 Yes
G3 35 M Glioblastoma, recurrent 33 7.9 462
G2 45 M Glioblastoma 40 9.5 933 Yes
H1 64 M Glioblastoma 68 22.6 230 Yes
H2 80 F Glioblastoma 85 40.0 71 No
H3 73 F Glioblastoma 36 8.5 38 No
H4 74 M Astrocytoma, anaplastic 78 35.0 22
H5 38 F Medulloblastoma 92 40.0 146 No
H6 40 F Oligodendroglioma 33 7.9 166*
H5 71 M Glioblastoma 52 13.3 275 Yes
J1 44 M Metastatic melanoma 32 7.6 2 No
J2 32 M Astrocytoma 80 40.0 2023 Yes
J3 58 F Glioblastoma 50 12.6 380 No
J4 10 F Medulloblastoma 16 4.7 2195*
K1 76 F Glioblastoma 56 15.0 21 No
K2 49 M Metastatic melanoma 38 9.0 251 Yes
K3 47 F Glioblastoma 33 7.9 156 No
K4 66 M Glioblastoma 27 6.6 101 No
L1 57 M Glioblastoma 27 6.6 218 No
L2 69 F Glioblastoma 16 4.7 46 No
M1 49 M Glioblastoma 7.3 3.3 111 Yes
M2 43 M Metastatic melanoma 8.7 3.6 91*
M3 36 F Medulloblastoma 6.9 3.3 936* Yes
M4 57 M Metastatic melanoma 11 3.9 18 No
M5 75 M Astrocytoma, anaplastic 66 20.9 331 Yes
M6 28 M Astrocytoma, anaplastic 54 14.1 219* No
N1 10 F Medulloblastoma 63 18.8 455* Yes
N2 42 M Astrocytoma, anaplastic 49 12.2 1301 Yes
N3 50 M Glioblastoma 100 40.0 326 Yes
O1 57 F Glioblastoma 49 12.2 416 Yes
P1 77 F Glioblastoma 42 10.0 80 No
P2 55 M Glioblastoma 48 11.9 239 Yes
P3 63 M Glioblastoma 40 9.5 65 No
R1 65 F Metastatic melanoma 22 5.7 112 Yes
R2 89 F Glioblastoma 23 5.9 71 No
R3 73 M Glioblastoma 17 4.9 71 No
R4 32 F Glioblastoma 64 19.5 986 Yes
S1 31 F Oligodendroglioma, anaplastic 55 14.6 2354 Yes
S2 65 F Glioblastoma 41 9.8 260 Yes
S3 40 M Metastatic melanoma 1.2 2.0 28 No
S4 53 M Glioblastoma 3.3 2.6 276 Yes
S5 63 F Glioblastoma 37 8.8 293
T1 53 M Oligoastrocytoma 58 16.0 6464* No
T2 48 F Glioblastoma 56 15.0 144 Yes
U1 40 F Glioblastoma 75 30.3 694* Yes
V1 66 F Glioblastoma 42 10.0 549 Yes
V2 32 F Glioblastoma 25 6.3 230 Yes
W2 10 M Medulloblastoma 11 3.9 69 Yes
W3 63 M Glioblastoma 71 25.4 230
Y1 69 M Glioblastoma 86 40.0 47 No
aResults from
3H-thymidine incorporation assays, examples of which are shown in Figure 1.
bPatients alive at the time of analysis are marked by an asterisk.
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swas no difference in survival by gender (the median survival times
were 8.9 months for females and 8.2 months for males, P¼0.9).
Survival was also related to tumour type (P¼0.0004, Table 2). For
patients with glioblastoma, the proportion alive after 1 year was
estimated to be 28%, compared with 64% for patients with
astrocytoma/oligodendroglioma, 67% for patients with medullo-
blastoma and 31% for patients with metastatic melanoma. Some of
the patients received radiotherapy (median dose 56Gy), but data
were not available for all patients. The median survival times for
patients receiving radiotherapy and those not receiving radio-
therapy were 12.1 and 2.6 months, respectively (P¼0.0004). Only
nine patients received chemotherapy, most of whom also received
radiotherapy.
There was no evidence of variation in culture cycle times by age
or gender (Table 2), but patients with astrocytomas or oligoden-
drogliomas had longer culture cycle times (the percentage with
culture cycle times of p10 days was 15%, as compared with 53%
for glioblastomas, 50% for medulloblastomas and 75% for
metastatic melanomas, P¼0.04). Patients who had received
radiotherapy also had longer culture cycle times (the percentage
with culture cycle times p10 days was 35%, compared with 58%
for those who did not receive radiotherapy and 78% for those
where treatment status was unknown, P¼0.04).
Patients were divided into two groups with culture cycle times of
p10 days and 410 days. Kaplan–Meier survival curves are
plotted in Figure 2A. The median survival times were 5.1 months
Table 2 Associations between survival, culture cycle time and demographic and treatment variables
No.
Median culture cycle
time in days
(95% CI)
Cycle p10 days,
n (%)
Cycle 410 days,
n (%)
Percentage alive
at 1 year
(95% CI)
a
Median survival
(95% CI) in
months
a
Age (years)
o30 8 11.4 (4.5–17.2) 4 (50%) 4 (50%) 45% (11–75%) 9.5
b
30–49 22 10.9 (7.6–19.5) 11 (50%) 11 (50%) 62% (37–79%) 30.7 (5.1–66.5)
50–59 12 12.0 (6.7–15.8) 5 (42%) 7 (58%) 42% (15–67%) 9.1 (3.3–13.7)
60–69 14 9.9 (8.8–23.0) 7 (50%) 7 (50%) 14% (2–37%) 7.3 (2.1–8.8)
70+ 14 11.7 (8.2–31.0) 7 (50%) 7 (50%) 21% (5–45%) 2.6 (1.2–10.9)
P¼0.9 P¼0.99 P¼0.002
+
Gender
Male 41 12.2 (8.9–17.5) 18 (44%) 23 (56%) 39% (24–54%) 8.2 (3.6–12.4)
Female 29 9.8 (8.3–13.3) 16 (55%) 13 (45%) 36% (19–54%) 8.9 (4.8–13.7)
P¼0.4 P¼0.4 P¼0.9
+
Tumour type
Glioblastoma 43 9. 8 (9.1–12.6) 23 (53%) 20 (47%) 28% (16–42%) 7.6 (4.7–9.1)
Astrocytoma/oligodendroglioma 13 16.0 (13.0–27.5) 2 (15%) 11 (85%) 64% (30–85%) 66.4 (9.5–104.1)
Medulloblastoma 6 9.9 (3.3–37.8) 3 (50%) 3 (50%) 67%
b —
c
Metastatic melanoma 8 6.7 (3.1–32.4) 6 (75%) 2 (25%) 31% (5–64%) 3.7 (0.1–12.4)
P¼0.06 P¼0.04 P¼0.0004
+
Radiotherapy
Yes 37 13.3 (9.8–18.7) 13 (35%) 24 (65% 51% (34–66%) 12.1 (8.5–18.4)
No 24 9.6 (7.3–14.0) 14 (58%) 10 (42%) 15% (4–33%) 2.6 (1.5–7.2)
Unknown 9 8.1 (4.9–24.2) 7 (78%) 2 (22%) 46% (11–76%) 9.6 (0.7–16.1)
P¼0.2 P¼0.04 P¼0.0003
+
+Log rank.
aCalculated using life table methods.
bNumbers too small for calculation.
cSurvival curve did not go below 50%.
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Figure 2 Kaplan–Meier survival plots of patients whose culture cycle times were p10 days (dashed line) and 410 days (solid line). (A) All patients.
(B) Patients with glioblastoma.
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s(95% CI (2.6–8.2)) and 12.5 months (95% CI (9.0–18.4)) for those
with culture cycle times of p10 days and 410 days, respectively
(P¼0.0009). Those with culture cycle times p10 days had a 2.4-
fold increased risk of death compared with those whose culture
cycle times were 410 days (95% CI (1.4–4.2), P¼0.001).
Adjustment for age and tumour type did not explain the
differences (Table 3), and adjustment for radiotherapy increased
the hazard ratio slightly, giving an estimated 2.9-fold increase in
risk among those with shorter culture cycle times (95% CI (1.5,
5.9), P¼0.003), although this estimate may be biased due to
missing data on radiotherapy.
For the 43 patients with glioblastoma, survival (Figure 2B) was
also shorter in those with culture cycle times p10 days (P¼0.04).
The median survival times were 6.5 months (95% CI (2.6–8.5)) for
those with culture cycle times p10 days and 9.0 (95% CI
(4.7–13.7)) for those with culture cycle times 410 days. Those
with culture cycle times p10 days had a 2-fold increased risk of
death compared with those with culture cycle times 410 days.
Survival was also associated with age in this subgroup (P¼0.05),
but culture cycle time was not related to age. For the other tumour
types, numbers were generally too small for meaningful compa-
risons of survival, but it was noteworthy that lower-grade gliomas
had a longer median culture cycle time (16.0 days) and were
associated with a longer median survival (66.4 months) than the
other tumour types.
DISCUSSION
The results show a significant relationship between survival and
culture cycle times derived from short-term cultures of tumour
samples taken at surgery from 70 patients with brain cancer.
Culture cycle times varied from 2 days to more than 40 days, and
the analysis method chosen was to divide patients into two
approximately equal groups with culture cycle times of p10 days
and 410 days and to compare Kaplan–Meier survival curves fore
each (Figure 2). These provided median survival times of 5.1 and
12.5 months, respectively, with a significant survival difference
(P¼0.0009). The study also demonstrated that culture cycle time
was independent of age and tumour type. The results can be
compared with those in a previous study of 16 patients with
ovarian cancer treated with carboplatin, where long culture cycle
times was associated with increased complete remission rate
(Marshall et al, 2002; Baguley and Marshall, 2004). Re-analysis of
this data using the methods employed here showed a median
survival time for the p10-day group of 2.9 months (95% CI
(0.1–11.8)), which was significantly shorter (P¼0.0003) than the
median survival time for the 410-day group of 25.6 months (95%
CI (11.8–100)). We also have evidence for similar relationships in
a larger group of ovarian cancer patients and in a group of patients
with melanoma (unpublished results). These studies are the first to
our knowledge to identify in vitro proliferation rates of primary
tumour cell cultures as a potential marker for survival.
The method used here to estimate culture cycle time diverges
significantly from the Tpot (potential doubling time) method that
has been employed extensively in the past as a cytokinetic
parameter (Wilson et al, 1988; Rew and Wilson, 2000) and deserves
comment. The stathmokinetic approach employed relies on the
principle that if cell cycle progression is blocked in a certain phase,
the proportion of cells in that phase will increase, whereas the
proportions in other phases decrease, and that the rate of change
of these proportions are a function of culture cycle time. In the
specific case of a mitotic poison such as paclitaxel, the number of
S-phase cells in control cultures will increase exponentially with
time, whereas the number of S-phase cells in drug-treated cultures
will decrease with time as a consequence of depletion of the pool of
G1-phase cells. The concentration of paclitaxel must be high
enough to prevent all cell division, accounting for the shape of the
dose–response curves in Figure 1. There are two methods of
deriving a relationship between ‘plateau’ values (P) for
3H-
thymidine incorporation in these dose–response curves and
culture cycle time (T). The first, employed here, is to use an
empirical formula T¼ 3.78/(log10 P) established from a series of
cell lines and making the assumption, which is reasonable for cell
lines, that the culture cycle time is equal to the doubling time. The
second is to base the calculation on a theoretical model for the cell
Table 3 Association of culture cycle time, clinical variables and survival
estimated using Cox regression
Hazard
ratio
95%
CI P-value
Model 1: culture cycle time only
Culture cycle time (days)
410 1.0
p10 2.4 (1.4–4.2) 0.001
Model 2: culture cycle time+age
Culture cycle time (days)
410 1.0
p10 2.5 (1.4–4.4) 0.001
Age group (years)
o30 1.0
30–49 1.0 (0.4–2.9) 0.97
50–59 1.7 (0.6–5.4) 0.33
60–69 3.6 (1.2–10.4) 0.02
70+ 3.4 (1.2–9.7) 0.02
Model 3: culture cycle time+age+tumour type
Culture cycle time (days)
410 1.0
p10 2.4 (1.3–4.4) 0.005
Age group (years)
o30 1.0
30–49 0.61 (0.20–1.9) 0.4
50–59 0.86 (0.26–2.8) 0.8
60–69 1.5 (0.47–4.6) 0.5
70+ 1.4 (0.46–4.6) 0.5
Tumour type
Glioblastoma 1.0
Medulloblastoma 0.15 (0.03–0.79) 0.03
Metastatic melanoma 1.3 (0.54–2.9) 0.6
Astrocytoma/oligodendroglioma 0.37 (0.13–1.1) 0.07
Model 4: culture cycle time+age+tumour type+radiotherapy (days)
Culture cycle time
410 1.0
p10 2.9 (1.5–5.9) 0.003
Age group (years)
o30 1.0
30–49 0.74 (0.25–2.2) 0.6
50–59 0.53 (0.16–1.7) 0.3
60–69 1.4 (0.47–4.5) 0.5
70+ 1.8 (0.60–5.6) 0.3
Tumour type
Glioblastoma 1.0
Medulloblastoma 0.21 (0.04–1.0) 0.05
Metastatic melanoma 0.93 (0.38–2.3) 0.9
Astrocytoma/oligodendroglioma 0.30 (0.09–0.92) 0.03
Radiotherapy
No 1.0
Yes 0.32 (0.16–0.63) 0.001
Unknown 0.14 (0.05–0.43) 0.001
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of the assumption that the transition from G1 phase to S phase is
controlled by a probability function (Basse et al, 2003). Such a
model fits experimental data for a number of cell lines treated
with paclitaxel and analysed using flow cytometry (Basse et al,
2004a,b). The theoretical model provides an equation
T¼ x/(log10 P), where x tends upwards towards 4.8, as the
G1-phase proportion increases towards 100%. Thus, the empirical
and theoretical estimates are comparable. There are potential
sources of error in this approach, as there are in the Tpot approach,
but the results suggest that the approach is valid.
The results from primary cultures can be compared with the
wealth of published data showing a relationship between Tpot
values and survival for several tumour types (Wilson et al, 1988;
Rew and Wilson, 2000). Although the culture cycle times and Tpot
values are quite different to each other, they both pertain to the
cytokinetic properties of tumour cells, and both indicate a
surprisingly wide range in culture cycle times. Unfortunately, we
have insufficient data linking culture cycle times to more
traditional indices of proliferation. Data for Ki-67 staining and
mitotic index were available from histology reports of some of the
patients, but these were was not correlated with either survival or
culture cycle time (results not shown). A larger controlled study
would be needed to compare culture cycle times with histological
indicators of cell proliferation or with molecular markers, such as
cyclin E expression (Keyomarsi et al, 2002) and gene expression
signatures (Nutt et al, 2003). However, one interpretation of the
data presented in this study is that cytokinetic properties of
tumour cells may be preserved, at least initially, after tumour
material is removed from the patient.
The question of why shorter culture cycle times, or shorter Tpot
values, are related to poor clinical outcome still remains to be
answered. Such times are not related directly to tumour growth
because tumour cells are in a state of continuous turnover, with the
net tumour volume doubling time usually in the order of months
rather than days (Watson, 1991). Shorter culture cycle times thus
reflect higher rates of tumour cell turnover in vivo, which in turn
might contribute to greater tumour aggressiveness. Rapid turnover
of tumour cells may lead to the generation of a more
immunosuppressive microenvironment, which could in turn be
linked to poor survival (Kim et al, 2006).
In conclusion, the overall survival of patients with brain cancers in
response to therapy most likely reflects a composite of response of
tumour cells and host responses to tumour, and it is clear from this
study that tumour cell cytokinetics may play a major role. Other
studies have demonstrated that radiotherapy and chemotherapy also
contribute to survival, raising the question of whether short-term
cultures could provide information on response to therapy as well as
on cytokinetics. Some of the patients in this study were treated with
radiotherapy (Table 1), and the median survival time for patients
receiving radiotherapy (12.1 months) was longer than that for
patients not receiving radiotherapy (2.6 months). Although part of
this difference will reflect patient selection, much is likely to reflect
the contribution of therapy. For 21 of the patients in this study, the
response of 7-day cultures to radiotherapy (up to 9Gy) was also
measured (Marshall et al, 2003), but no relationship to survival was
found (results not shown). Further research will be required to
develop accurate methods of assessing the relative contributions of
intrinsic tumour cytokinetics and treatment to survival of patients
with brain cancer.
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